News & Analysis as of

Canada Competition Act Pharmaceutical Patents

Smart & Biggar

Competition Tribunal refuses JAMP leave to commence ustekinumab abuse of dominance application

Smart & Biggar on

As we previously reported, JAMP sought leave to commence an application against Janssen under the abuse of dominance provisions of the Competition Act (the Act), relating to ustekinumab (Janssen’s STELARA and FINLIUS). This...more

Smart & Biggar

Competition Bureau closes two investigations into pharmaceutical patent litigation settlements

Smart & Biggar on

On May 20, 2022, the Competition Bureau announced that it closed two investigations into pharmaceutical patent litigation settlement agreements as evidence gathered during the two investigations suggested the agreements did...more

2 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide